Prosecution Insights
Last updated: October 04, 2026
Application No. 18/032,895

METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES

Non-Final OA §112
Filed
Apr 20, 2023
Priority
Oct 23, 2020 — provisional 63/104,898 +2 more
Examiner
VALENROD, YEVGENY
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Madrigal Pharmaceuticals Inc.
OA Round
2 (Non-Final)
73%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
744 granted / 1025 resolved
+12.6% vs TC avg
Strong +25% interview lift
Without
With
+25.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
45 currently pending
Career history
1062
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
38.0%
-2.0% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
21.0%
-19.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1025 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 6/5/26 has been entered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-10, 13-14, 16, 18, 20, 23 and 25-32 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of preparing compounds (III), (IV), (V), (III-a), and (IV-a) wherein R1, R2, R3, R4, R5 and R6 are selected from moieties depicted in claims 9, 10, 11, 12, 22, 24, 27, does not reasonably provide enablement for a method where R1, R2, R3, R4, R5 and R6 are selected form the moieties encompassed by the full scope of herein rejected claims. The specification does not enable any person skilled in the art to which it pertains, or with which it is nearly connected, to practice the invention commensurate in scope with these claims. Nature of invention: The invention is directed to multistep synthesis of chemical compound. In claims 1, the synthesis comprises reacting compound (I) and (II) to produce (III), reducing (III) to (IV). In claim 3, compound (IV) is further reacted to produce (V). Independent claim 4 is directed to the same method of claim 1, but comprises an additional step where compound (III) is reacted to alkylate the amide nitrogen to produce (III-a) and the alkylated product is carried through the rest of the steps. Breadth of claims: The claims are broad because of the diverse nature of the substituents in positions R1, R2, R3, R4, R5 and R6. The example below demonstrates the breadth of substituents for R3 and Ra, but they are identical for substituents R1 and R2, as well as Rb and Rc: PNG media_image1.png 588 620 media_image1.png Greyscale The scope of R1, R2, R3, R4, R5 and R6 encompasses nucleophilic groups (e.g. amines), electrophilic groups (e.g. carbonyls), groups that are reactive under claimed reaction conditions (e.g. ketones can be reduced under Pd/H2), sterically large groups (e.g. cycloalkyl substituted with cycloalkyl). In view of the divergent size and reactivity of the claimed groups, a skilled artisan would question if compounds carrying such groups would be reactive under the conditions claimed in a manner that would produce the claimed products. State of prior art: The claimed method is free of prior art. Level of predictability in the art MPEP 2164.03: The "predictability or lack thereof" in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. If one skilled in the art can readily anticipate the effect of a change within the subject matter to which the claimed invention pertains, then there is predictability in the art. On the other hand, if one skilled in the art cannot readily anticipate the effect of a change within the subject matter to which that claimed invention pertains, then there is lack of predictability in the art. Accordingly, what is known in the art provides evidence as to the question of predictability. In particular, the court in In re Marzocchi, 439 F.2d 220, 223-24, 169 USPQ 367, 369-70 (CCPA 1971), stated: [I]n the field of chemistry generally, there may be times when the well-known unpredictability of chemical reactions will alone be enough to create a reasonable doubt as to the accuracy of a particular broad statement put forward as enabling support for a claim. This will especially be the case where the statement is, on its face, contrary to generally accepted scientific principles. Most often, additional factors, such as the teachings in pertinent references, will be available to substantiate any doubts that the asserted scope of objective enablement is in fact commensurate with the scope of protection sought and to support any demands based thereon for proof. In the currently claimed method, the reagents comprise substituents that would cause a skilled artisan to question their effect on the claimed chemical transformations. The substituents comprise groups that are themselves capable of reacting under the claimed conditions. For example, in preparation of compound (IV) from compound (III), groups other than the NO2 can be reduced. Groups such as carbonyl containing compounds. In another example, preparation of compound (III-a) requires a nucleophilic substitution of a halogen attached to R6. However, XR6 comprises compounds that would not be reactive or even stable such as XOH. Also compound III comprises groups that are more nucleophilic than the amide nitrogen and would preferentially react with XR6, such as primary amines (alkyl substituted with NH2). Amount of direction and working examples: Working examples comprise non-reactive aryl halogens and small alkyl groups as substituents for R1, R2, R3, R4, R5 and R6. These are the substituents found in claims 9, 10, 11, 12, 22, 24 and 27. Quantity of experimentation: To enable practice the full scope of invetion, a skilled artisan would need to devise a synthetic protocol and prepare the thousands of starting materials and test each combination of starting materials in the claimed synthetic method. The amount of experimentation is immense. Due to unpredictability that is inherent in chemical synthesis and a limited exemplified scope of substituents, a skilled artisan would not be able to practice the full scope of the claimed method without undertaking a significant quantity of undue experimentation. Claim objections Claims 11, 12 and 22 are objected to as being dependent on a rejected claim. Allowed claims Claim 24 is allowed. Conclusion Claims 1, 3-10, 11-14, 16, 18, 20, 22-24 and 25-32 are pending Claims 1, 3-10, 13-14, 16, 18, 20, 23 and 25-32 are rejected Claims 11, 12 and 22 are objected to Claim 24 is allowed Any inquiry concerning this communication or earlier communications from the examiner should be directed to YEVGENY VALENROD whose telephone number is (571)272-9049. The examiner can normally be reached Mon-Fri 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YEVGENY VALENROD/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Apr 20, 2023
Application Filed
Aug 08, 2025
Non-Final Rejection mailed — §112
Feb 06, 2026
Response Filed
Jun 05, 2026
Request for Continued Examination
Jun 08, 2026
Response after Non-Final Action
Sep 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746233
REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF ARTERIAL STIFFNESS
4y 7m to grant Granted Sep 29, 2026
Patent 12740965
SOTAGLIFLOZIN FOR IMPROVING LEFT ATRIAL FUNCTION
3y 2m to grant Granted Sep 22, 2026
Patent 12735383
LACTATE/KETONE BODY ESTERS
3y 4m to grant Granted Sep 15, 2026
Patent 12728155
COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
4y 8m to grant Granted Sep 08, 2026
Patent 12697331
METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS
3y 9m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
73%
Grant Probability
98%
With Interview (+25.1%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1025 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month